A detailed history of Paradigm Biocapital Advisors LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,400,574 shares of JANX stock, worth $121 Million. This represents 3.93% of its overall portfolio holdings.

Number of Shares
2,400,574
Previous 1,564,452 53.45%
Holding current value
$121 Million
Previous $65.5 Million 66.41%
% of portfolio
3.93%
Previous 2.65%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$35.29 - $50.26 $29.5 Million - $42 Million
836,122 Added 53.45%
2,400,574 $109 Million
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $54.9 Million - $101 Million
1,564,452 New
1,564,452 $65.5 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.1B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Paradigm Biocapital Advisors LP Portfolio

Follow Paradigm Biocapital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.